ReviewFrontiers in oncology2017
Smoking and Lung Cancer: A Geo-Regional Perspective.
Review in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Lung cancer mortality and associated predictors: systematic review using 32 scientific research findings.Frontiers in oncology · 2023Pooled it
- Drugs for preventing lung cancer in healthy people.The Cochrane database of systematic reviews · 2020Pooled it
- Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions.Nature reviews. Clinical oncology · 2025Review
- Impact of global smoking prevalence on mortality: a study across income groups.BMC public health · 2024Article
- Prediction of the stage shift growth of early-stage lung adenocarcinomas by volume-doubling time.Quantitative imaging in medicine and surgery · 2024Article
- Modifiable risk factors for cancer in the middle East and North Africa: a scoping review.BMC public health · 2024Article
- An overview of traditional smoking cessation interventions and E-cigarettes.Frontiers in pharmacology · 2024Review
- Difference of serum tumor markers in different clinical stages of elderly patients with non-small cell lung cancer and evaluation of diagnostic value.Journal of medical biochemistry · 2023Article
- Identification of a polycomb group-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.Journal of thoracic disease · 2023Article
- Diagnosis and management of patients with stage III non‑small cell lung cancer: A joint statement by the Lebanese Society of Medical Oncology and the Lebanese Pulmonary Society (Review).Oncology letters · 2023Review
- The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer.International journal of molecular sciences · 2023Review
- Zengshengping improves lung cancer by regulating the intestinal barrier and intestinal microbiota.Frontiers in pharmacology · 2023Article
- A serum microRNA signature for enhanced selection of people for lung cancer screening.Cancer communications (London, England) · 2022Article
- Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
- Cell-by-Cell: Unlocking Lung Cancer Pathogenesis.Cancers · 2022Review
- Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung.Cancer prevention research (Philadelphia, Pa.) · 2022Observational
- circ_0000567/miR-421/Journal of Cancer · 2022Article
- Circular RNA circENTPD7 suppresses the accumulation of PTEN to promote cell proliferation in non-small cell lung cancer.Genetics and molecular biology · 2022Article
- Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.BMC pulmonary medicine · 2021Article
- Ultrasound-targeted microbubble destruction mediated miR-492 inhibitor suppresses the tumorigenesis in non-small cell lung cancer.Annals of medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) represents the most frequently diagnosed subtype of this morbid malignancy. NSCLC is causally linked to tobacco consumption with more than 500 million smokers worldwide at high risk for this fatal malignancy. We are currently lagging in our knowledge of the early molecular (e.g., genomic) effects of smoking in NSCLC pathogenesis that would constitute ideal markers for early detection. This limitation is further amplified when considering the variable etiologic factors in NSCLC pathogenesis among different regions around the globe. In this review, we present our current knowledge of genomic alterations arising during early stages of smoking-induced lung cancer initiation and progression, including discussing the premalignant airway field of injury induced by smoking. The review also underscores the wider spectra and higher age-adjusted rates of tobacco (e.g., water-pipe smoke) consumption, along with elevated environmental carcinogenic exposures and relatively poorer socioeconomic status, in low-middle income countries (LMICs), with Lebanon as an exemplar. This "cocktail" of carcinogenic exposures warrants the pressing need to understand the complex etiology of lung malignancies developing in LMICs such as Lebanon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.